Anthony JC, Warner L, Kessler R. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994; 2: 244–68

Budney, Alan J., et al. Review of the validity and significance of cannabis withdrawal syndrome. American journal of Psychiatry 161.11 (2004): 1967-1977

Russo, Ethan B., Alice P. Mead, and Dustin Sulak. Current status and future of cannabis research. Clinical Researcher 29.2 (2015): 58-63.

Russo, E. B. 2016. Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues. Frontiers in Pharmacology 7:309.

Abel, Ernest L. Changes in anxiety feelings following marijuana smoking. Addiction 66.3 (1971): 185-187.

Abrams, Donald I., and M. Guzman. Cannabis in cancer care. Clinical Pharmacology & Therapeutics 97.6 (2015): 575-586

Huang, Yu-Hui Jenny, et al. An epidemiologic review of marijuana and cancer: an update. Cancer Epidemiology and Prevention Biomarkers 24.1 (2015): 15-31.

Machado Rocha, Francisco C., et al. Therapeutic use of Cannabis sativa on chemotherapy‐induced nausea and vomiting among cancer patients: systematic review and meta‐analysis. European journal of cancer care 17.5 (2008): 431-443.

Portenoy, Russell K., et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. The Journal of Pain 13.5 (2012): 438-449.

Russo, Ethan B., Geoffrey W. Guy, and Philip J. Robson. Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis‐Based Medicine. Chemistry & biodiversity 4.8 (2007): 1729-1743.

Ward, Sara Jane, et al. Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice. Anesthesia and analgesia 113.4 (2011): 947.

Naguib, Mohamed, et al. Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system. Anesthesia and analgesia 114.5 (2012): 1104.

Burgos, Elisa, et al. Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells. European journal of pharmacology 682.1 (2012): 62-72.

Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systema0c review. Drug Metab Rev. 2014 Feb;46(1):86-95.

Green, Anita J., and Kay De‐Vries. Cannabis use in palliative care–an examination of the evidence and the implications for nurses. Journal of clinical nursing 19.17‐18 (2010): 2454-2462.

Ladin, Daniel A., et al. Preclinical and clinical assessment of cannabinoids as anti-cancer agents. Frontiers in pharmacology 7 (2016): 361.

Singh, Yadvinder, and Chamandeep Bali. Cannabis Extract Treatment for Terminal Acute Lymphoblastic Leukemia with a Philadelphia Chromosome Mutation. Case reports in oncology 6.3 (2013): 585-592.

Kander, J. Cannabis for the Treatment of Cancer: The Anticancer Activity of Phytocannabinoids and Endocannabinoids 4th edition, 2017.

 Gardner, F. Doctors stress need to document anti-cancer effects of Cannabis ‘oil’. O’Shaughnessy’s: The Journal of Cannabis in Clinical Practice. Winter/Spring 2013.

Torres, Sofía, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Molecular cancer therapeutics 10.1 (2011): 90-103.

Ward, N. J., and L. Dye. Cannabis and driving: a review of the literature and commentary. ROAD SAFETY RESEARCH REPORT 12 (1999).

Armentano, Paul. Should Per Se Limits Be Imposed For Cannabis? Equating Cannabinoid Blood Concentrations with Actual Driver Impairment: Practical Limitations and Concerns. Humboldt Journal of Social Relations 35 (2013): 41-51.

Scott, Katherine A., Angus G. Dalgleish, and Wai M. Liu. The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Molecular cancer therapeutics (2014).

Bar-Sela, Gil, et al. Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome. Cancers 12.9 (2020): 2447.

Taha, Tarek, et al. Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies. The oncologist 24.4 (2019): 549.

Carbone, Federico, et al. Cannabinoid receptor type 2 activation in atherosclerosis and acute cardiovascular diseases. Current medicinal chemistry 21.35 (2014): 4046-4058

Waldman, M., et al. An ultra-low dose of tetrahydrocannabinol provides cardioprotection. Biochemical pharmacology 85.11 (2013): 1626-1633

Pacher, Pal, et al. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nature Reviews Cardiology 15.3 (2018): 151. While cannabis can protect the cardiovascular system, an inappropriate dose can be dangerous for patients with unstable cardiovascular disease.

Whiting, Penny F., et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA 313.24 (2015): 2456-2473

Tait, Robert J., Andrew Mackinnon, and Helen Christensen. Cannabis use and cognitive function: 8‐year trajectory in a young adult cohort. Addiction 106.12 (2011): 2195-2203

Hickman, et al. If cannabis caused schizophrenia—how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. Addiction, 104, 1856– 1861. 2009

Vandrey, Ryan, et al. Cannabinoid dose and label accuracy in edible medical cannabis products. Jama 313.24 (2015): 2491-2493

Zamora-Valdés, Daniel, et al. The endocannabinoid system in chronic liver disease. Ann Hepatol 4.4 (2005): 248-254

Sañudo-Peña, M. Clara, et al. Activational role of cannabinoids on movement. European journal of pharmacology 391.3 (2000): 269-274.

Stout, Stephen M., and Nina M. Cimino. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug metabolism reviews 46.1 (2014): 86-95.

https://reference.medscape.com/drug-interactionchecker

McPartland, John M., Dan J. Blanchon, and Richard E. Musty. CLINICAL STUDY: Cannabimimetic effects modulated by cholinergic compounds. Addiction biology 13.3‐4 (2008): 411-415.

Cairns, Elizabeth A., William H. Baldridge, and Melanie EM Kelly. The endocannabinoid system as a therapeutic target in glaucoma. Neural plasticity 2016 (2016)

Russo, E. B., et al. Cannabis improves night vision: a case study of dark adaptometry and scotopic sensitivity in kif smokers of the Rif mountains of northern Morocco. Journal of ethnopharmacology 93.1 (2004): 99-104

Smith, Paul F., and Yiwen Zheng. Cannabis, cannabinoids and tinnitus. Journal of Pharmacology and Drug Metabolism 1.1 (2014): 1

Hillard, Cecilia J. Endocannabinoids and the endocrine system in health and disease. Endocannabinoids. Springer, Cham, 2015. 317-339

Kim HS, Anderson JD, Saghafi O, Heard KJ, Monte AA. Cyclic vomiting presentations following marijuana liberalization in Colorado. Acad Emerg Med. 2015 Jun. 22 (6):694-9

McPartland, John M. The endocannabinoid system: an osteopathic perspective.The Journal of the American Osteopathic Association 108.10 (2008): 586-600

Rajavashisth, Tripathi B., et al. Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III.BMJ open 2.1 (2012): e000494

Penner, Elizabeth A., Hannah Buettner, and Murray A. Mittleman. The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. The American journal of medicine 126.7 (2013): 583-589.

Cluny, Nina L., et al. Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Δ 9-Tetrahydrocannabinol. PloS one 10.12 (2015): e0144270

Palomares, Belén, et al. Tetrahydrocannabinolic acid A (THCA-A) reduces adiposity and prevents metabolic disease caused by diet-induced obesity. Biochemical Pharmacology 171 (2020): 113693.

Jadoon, Khalid A., et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care 39.10 (2016): 1777-1786

Ramaekers, Johannes G., et al. Dose related risk of motor vehicle crashes after cannabis use. Drug and alcohol dependence 73.2 (2004): 109-119

Koppel, Barbara S., et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82.17 (2014): 1556-1563

Lynch, M. E., and Mark A. Ware. Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials. Journal of neuroimmune pharmacology 10.2 (2015): 293-301.

Noyes, R., et al. The analgesic properties of delta-9-tetrahydrocannabinol. Clin Pharmacol Ther 18.1 (1975): 84-89.

Portenoy, Russell K., et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. The Journal of Pain 13.5 (2012): 438-449

Mechoulam, Raphael, David Panikashvili, and Esther Shohami. Cannabinoids and brain injury: therapeutic implications. Trends in molecular medicine 8.2 (2002): 58-61

National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. National Academies Press, 2017. Full text available free: https://www.nap.edu/download/24625

Manchikanti, Laxmaiah, and Angelie Singh. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain physician 11.2 Suppl (2008): S63-S88.

Muhuri, Pradip K., Joseph C. Gfroerer, and M. Christine Davies. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Review 17 (2013).

Krebs, Erin E., et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. Jama 319.9 (2018): 872-882.

Appendino, Giovanni, et al. Antibacterial cannabinoids from Cannabis sativa: a structure− activity study. Journal of natural products 71.8 (2008): 1427-1430.

García-Arencibia, Moisés, et al. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain research 1134 (2007): 162-170

Whan, Lynne B., et al. Effects of delta-9-tetrahydrocannabinol, the primary psychoactive cannabinoid in marijuana, on human sperm function in vitro. Fertility and sterility 85.3 (2006): 653-660

National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. National Academies Press, 2017.

Hayes, Janice S., et al. Five-year follow-up of rural Jamaican children whose mothers used marijuana during pregnancy. The West Indian medical journal 40.3 (1991): 120-123

Baker, Teresa, et al. Transfer of Inhaled Cannabis Into Human Breast Milk. Obstetrics & Gynecology 131.5 (2018): 783-788

Tetrault, Jeanette M., et al. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Archives of internal medicine167.3 (2007): 221-228.

Sulak, Dustin, Russell Saneto, and Bonni Goldstein. The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy & Behavior 70 (2017): 328-333.

Kogan, Natalya M., et al. Cannabidiol, a Major Non‐Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts. Journal of Bone and Mineral Research 30.10 (2015): 1905-1913